Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
6Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
X4 Pharmaceuticals, Inc. (XFOR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
2Distinct source URLs
9High confidence
0.875Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
X4 Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
GENZYME-CORPORATION
GENZYME-CORPORATION
90%
In July 2014, we entered into a license agreement (the “Genzyme Agreement”) with Genzyme Corporation ("Genzyme"), a wholly owned subsidiary of Sanofi, pursuant to which we were granted an exclusive l…
X4 Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
ABBISKO-THERAPEUTICS-CO-LTD
ABBISKO-THERAPEUTICS-CO-LTD
92%
We also have a license agreement with Abbisko Therapeutics Co. Ltd. ("Abbisko"), which granted Abbisko the exclusive right to perform regulatory activities on, manufacture and distribute mavorixafor …
NORGINE
NORGINE
92%
On January 13, 2025, we announced a license and supply agreement (the “Norgine Agreement”) with Norgine, pursuant to which Norgine was granted an exclusive license to distribute, market and sell our …
NORGINE-PHARMA-UK-LTD
NORGINE-PHARMA-UK-LTD
92%
The Company entered into a license and supply agreement (the “Norgine Agreement”) with Norgine Pharma UK Ltd. (“Norgine”).
TAIBA-MIDDLE-EAST-FZ-LLC
TAIBA-MIDDLE-EAST-FZ-LLC
92%
In February 2025, we announced that we had entered into an agreement with Taiba Middle East Fz LLC ("taiba rare") to distribute and commercialize XOLREMDI for the treatment of WHIM syndrome in select…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from XFOR graph: imated life of the customer relationship in proportion to the value of license, products and services provided. Rese…
SNYNF
Sanofi
72%
imated life of the customer relationship in proportion to the value of license, products and services provided. Research and Development Programs— Proceeds under the research and development incentiv…
X4 Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
XFOR-DEBT-13657
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
XFOR-DEBT
Debt stack $54.6M
90%
Market cache reports total debt of $54.6M.
XFOR-DEBT-13656
Warrants outstanding: 15241246
90%
xbrl warrant detail from xbrl 2025-12-31.
X4 Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for X4 Pharmaceuticals, Inc..
X4 Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
XFOR-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 82 tracked holders.
X4 Pharmaceuticals, Inc. Extended Supply Chain Network
